TRAVERE THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Per Diluted Share
TRAVERE THERAPEUTICS, INC. (TVTX) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.37 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2026-06-30 was -$0.37.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2026-03-31 was -$0.40.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was -$0.14.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-03-31 was -$0.47.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2025 was -$0.57.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$4.07.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$5.07.
- TRAVERE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$5.20.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.37 10-Q · filed 2026-08-04 | -$0.77 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | -$0.40 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | -$0.57 10-K · filed 2026-02-19 | |||
| 2025-06-30 | -$0.14 10-Q · filed 2026-08-04 | -$0.61 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | -$0.47 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -$4.07 10-K · filed 2026-02-19 | |||
| 2024-09-30 | -$0.70 10-Q · filed 2025-10-30 | -$3.36 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | -$0.90 10-Q · filed 2025-08-06 | -$2.66 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$1.76 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$1.16 10-K · filed 2024-02-20 | -$5.07 10-K · filed 2026-02-19 | ||
| 2023-09-30 | -$1.17 10-Q · filed 2024-10-31 | -$3.91 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | -$1.34 10-Q · filed 2024-08-01 | -$2.75 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | -$1.42 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$1.33 10-K · filed 2024-02-20 | -$5.20 10-K · filed 2025-02-21 | ||
| 2022-09-30 | -$1.31 10-K · filed 2024-02-20 | -$3.86 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | -$1.25 10-K · filed 2024-02-20 | |||
| 2022-03-31 | -$1.29 10-K · filed 2024-02-20 | |||
| 2021-12-31 | -$3.63 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |